Mon panier

NKp46

NKp46 Informations sur la molécule

Nom anglaisNatural cytotoxicity triggering receptor 1Nombre de médicaments commercialisés0
Nombre de médicaments cliniques3Alias de la cibleNK cell-activating receptor,NK-p46,Lymphocyte antigen 94 homolog,NKp46,hNKp46,Lymphocyte Antigen 94 Homolog (Activating NK-Receptor; NK-P46),Natural killer cell p46-related protein,LY94,Lymphocyte Antigen 94 (Mouse) Homolog (Activating NK-Receptor; NK-P46),CD335 Antigen,CD335
Phase de R&D la plus avancéePhase 2 Clinical
Nom anglaisNatural cytotoxicity triggering receptor 1
Alias de la cibleNK cell-activating receptor,NK-p46,Lymphocyte antigen 94 homolog,NKp46,hNKp46,Lymphocyte Antigen 94 Homolog (Activating NK-Receptor; NK-P46),Natural killer cell p46-related protein,LY94,Lymphocyte Antigen 94 (Mouse) Homolog (Activating NK-Receptor; NK-P46),CD335 Antigen,CD335
Nombre de médicaments commercialisés0
Nombre de médicaments cliniques3
Phase de R&D la plus avancéePhase 2 Clinical

NKp46 Liste de produits

  • Attribut

    Protein (16)Cell (2)Antibody (1)

  • Bibliothèque de produits

    En ligne (19)

  • Espèces

    Human (12)Cynomolgus (3)Mouse (4)

  • Étiquette

    Fc Tag (4)His Tag (6)Llama IgG Fc Tag (2)Fc Tag & Avi Tag (1)His Tag & Avi Tag (3)- (2)Tag Free (1)

  • Marqueur

    Unconjugated (10)Biotin-labeled (5)- (2)PE Labeled (1)FITC Labeled (1)

NKp46Contexte de la molécule

Natural cytotoxicity triggering receptor 1 (NCR1) is also known as Natural killer cell p46-related protein (NK-p46), Lymphocyte antigen 94 homolog (LY94), CD antigen CD335, which belongs to the natural cytotoxicity receptor (NCR) family. NCR1 contains two Ig-like (immunoglobulin-like) domains. NCR1 interacts with CD247 and FCER1G. NCR1 / CD335 may contribute to the increased efficiency of activated natural killer (NK) cells to mediate tumor cell lysis.

NKp46Alias de la molécule

NCR1,LY94,CD335,NK-p46,hNKp46

Informations sur les médicaments cliniques

Nom anglaisCode de recherchePhase de R&DEntrepriseIndicationEssai clinique
NY-303NY-303Phase 2 ClinicalNAYA Biosciences IncCarcinoma, Hepatocellular; Solid tumours
Details
IPH-6501IPH-6501; IPH-65Phase 2 ClinicalInnate Pharma SALymphoma, Follicular; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Non-Hodgkin; Neoplasms
Details
SAR-443579SAR-443579; SAR443579; SAR'579; IPH6101; IPH-6101Phase 1 ClinicalSanofiBlastic Plasmacytoid Dendritic Cell Neoplasm; Hematologic Diseases; Leukemia, B-Cell; Leukemia, Myeloid, Acute; Myelodysplastic Syndromes; Precursor Cell Lymphoblastic Leukemia-Lymphoma
Details
  • Liste de produits
  • Informations sur les médicaments cliniques